Bio View (BIOV.TA) Aktie Kurs

BioView Ltd. engages in the research, development, marketing, and sales of imaging systems computerized to identify abnormal cells. The firm manufactures and assembles, markets and services an automated cell diagnostic system for use in cytology, cytogenetic, hematology and pathology laboratories. The workstation is called Duet, which provides automated detection, classification, analysis, and counting of cells for diagnosis and study. Additionally, Duet provides a method to analyze both the morphology and the genetic content of the same cell. The firm has applications in Cancer diagnosis and follow-up of minimal-residual disease (MRD); in pre-natal and post-natal Cytogenetic analyses in the analysis of sperm cells and rare-cell detection (RCD). In 2005, the Company introduced two new scanning workstations: the ALLEGRO, for automated scanning of Fluorescence in-situ Hybridization (FISH) probes without Brightfield scanning, and the ACCORD, for the semi-automated imaging of FISH for breast cancer (Her-2/Neu) and for FISH on tissue.